C4 Therapeutics, Inc.(CCCC)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

C4 Therapeutics, Inc. (CCCC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CCCC at 18.2/100 on a 32-signal composite quality model, placing it at rank #2,812 of 2,962 stocks — the bottom half of the AI-ranked universe. CCCC scores in the top quartile across institutional flow (97.6). Areas of concern include free cash flow (4.0) and profitability (4.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), C4 Therapeutics, Inc. reports quarterly revenue of $6.6M, net income of $-23.6M, free cash flow of $-1.6M. Top institutional holders of CCCC by reported 13-F value include MORGAN STANLEY, RA CAPITAL MANAGEMENT, L.P., BlackRock, based on the most recent SEC filings. CCCC trades on the Nasdaq exchange and files with the SEC under CIK 1662579. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CCCC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for C4 Therapeutics, Inc. directly from SEC EDGAR.